Brokers quote A difference hundred Watson Biology 134 times times a record

As the gem ushered in its first birthday, the starting price-earnings ratio of the gem has once again hit record highs. According to Watson Biology (300142) yesterday (October 29) disclosed the initial public offering of shares and on the Gem IPO announcement, The company's first-rate P/E ratio is as high as 133.8 times times, refreshing the top-price earnings ratio of 126.67 times times that of the Gold Dragon Electromechanical (300032, closing 19.32). In the end, Watson's life is priced at 95 yuan/share.　　Online distribution of 20 million shares, the network under the placing of 5 million shares.　　Earlier, the A-share market had seen 7 companies at the time of issuance of more than 100 times times the price-earnings ratio, all from the gem, Watson became the 8th and the highest in a first-price price-to-earnings ratio of more than a company.　　Brokers and funds into a high price distribution of the hands from the range of inquiry, is also a record opened the gap, declared the highest price of 130 yuan/unit, the number of the proposed declaration is 5 million shares, and the lowest declared price of 20 yuan/share, the number of declarations for 1 million shares, two declared the difference of up to 110 yuan! In addition, the declared price of more than 100 yuan/share of a total of 9 prices, in addition to the maximum price of 130 yuan/unit, the other 8 prices are 110 yuan/unit, 108 yuan/unit, 105 yuan/unit, 104 Yuan/unit, 102 Yuan/unit, 101.4 Yuan/unit, 101 Yuan/unit, 100 yuan/share.　　This shows the madness of the Organization. According to the announcement, Watson biology this issue price 95.00 yuan/shares corresponding cumulative purchase quantity of 231.3 million shares, corresponding to the net oversubscribed multiple subscription multiples of 46.26 times times, corresponding to the 2009 diluted earnings ratio of 133.8 times times.　　The weighted average number of all stock placements is 92.47 yuan, the median number is 92.00 yuan, and the issuer price is higher than the weighted average and median of all the stock placing objects quoted.　　The starting price-earnings ratio is a record, and the driver behind the scenes remains the fund and securities companies involved in the inquiry. According to the inquiry object classification, the object of participation mainly has 6 kinds, among them, the fund company and the Securities company have 89 and 53 to participate in the quotation respectively, but the fund company gives the quotation interval for 73 yuan/shares ~110 Yuan/shares, the securities company is 20 yuan/shares ~130 Yuan/stock,　　It can be seen that the two institutions of the crazy Rob directly led to Watson's biology into the history of the first "high price" issued by the stock! In contrast, the financial companies are relatively rational, 6 financial companies offer range of 54.6 yuan/share ~97.5 yuan/share.　　11 Trust companies offer a higher price, the interval of 70.51 yuan/share ~110 yuan/shares, insurance companies and QFII each have 1 participating in the offer, respectively, 100 Yuan/unit and 91 yuan/share.　　The final determination will be published on the Internet 20 million shares, and close to the high price, it is bound to allow a lot of retail investors can not participate, the industry believes that do not rule out like the original Cologne pharmaceutical (002422, closing price of 117.83 Yuan), as in accordance with the ceiling of the purchase may have a good rateThe company said the pricing was reasonable, although it issued a price-earnings ratio of more than 100 times times. Watson biological aspects of the gem 6 comparable companies and 4 business-like companies to compare the 2009 P/E rating of 59.86 times times and 72.91 times times respectively, the company said, according to the issue price of 95.00 yuan/unit calculation,　　The issue of a 133.8 times-fold P/E ratio (to deduct the low value before and after the non-recurrent profit and loss), the price is higher than the comparable company average, but given the company's growth, it is appropriate to give a certain premium. Although at a price-earnings ratio of up to 133.8 times times, but from the data, Watson's first day after the listing will still be better performance, with the previous 7 gem companies more than 100 times times P/E earnings on the first day of the debut of the company, the smallest increase in Kang frequency (300048, closing price of 46.36 Yuan) rose 23.77%,　　The biggest three-dimensional silk (300056, closing price of 38.65 Yuan) rose 75.82%, but these companies mostly out of the one-step trend, the current stock price and the date of the listing is not big.　　The researchers also said that Watson, as the most powerful domestic research and development of the biological vaccine companies, with scarce attributes, the looting is also very normal. The recent listing of another biological company, intelligent flying creature (300122, closing price of 40.99 Yuan), also in the Watson bio-high price of the stimulus, spurred by a sharp rise, yesterday rose 5.24%.